Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Initial experiences with isolated limb perfusion for unresectable melanoma of the limb.

Romics L Jr, Dy EA, Coffey JC, Herlihy D, Aftab F, Chaudhry MZ, Fogarty K, O'Donnell JA, Redmond HP.

Ir J Med Sci. 2011 Jun;180(2):517-20. doi: 10.1007/s11845-010-0664-2. Epub 2011 Feb 3.

PMID:
21287291
2.
3.

Long-term outcome of isolated limb perfusion with tumour necrosis factor-α for patients with melanoma in-transit metastases.

Deroose JP, Grünhagen DJ, van Geel AN, de Wilt JH, Eggermont AM, Verhoef C.

Br J Surg. 2011 Nov;98(11):1573-80. doi: 10.1002/bjs.7621. Epub 2011 Jul 8.

PMID:
21739427
4.

Isolated limb perfusion for unresectable melanoma of the extremities.

Noorda EM, Vrouenraets BC, Nieweg OE, van Geel BN, Eggermont AM, Kroon BB.

Arch Surg. 2004 Nov;139(11):1237-42.

PMID:
15545572
5.

Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients.

Takkenberg RB, Vrouenraets BC, van Geel AN, Nieweg OE, Noorda EM, Eggermont AM, Kroon BB.

J Surg Oncol. 2005 Aug 1;91(2):107-11.

PMID:
16028280
6.

Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study.

Liénard D, Eggermont AM, Koops HS, Kroon B, Towse G, Hiemstra S, Schmitz P, Clarke J, Steinmann G, Rosenkaimer F, Lejeune FJ.

Melanoma Res. 1999 Oct;9(5):491-502.

PMID:
10596916
7.

Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.

Grünhagen DJ, van Etten B, Brunstein F, Graveland WJ, van Geel AN, de Wilt JH, Eggermont AM.

Ann Surg Oncol. 2005 Aug;12(8):609-15. Epub 2005 Jun 22.

PMID:
15968498
8.

Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.

Vrouenraets BC, Eggermont AM, Hart AA, Klaase JM, van Geel AN, Nieweg OE, Kroon BB.

Eur J Surg Oncol. 2001 Jun;27(4):390-5.

PMID:
11417986
9.

Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.

Noorda EM, Vrouenraets BC, Nieweg OE, van Geel AN, Eggermont AM, Kroon BB.

Eur J Surg Oncol. 2006 Apr;32(3):318-24. Epub 2006 Jan 18.

PMID:
16412605
10.

Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.

Noorda EM, Vrouenraets BC, Nieweg OE, van Coevorden F, van Slooten GW, Kroon BB.

Cancer. 2003 Oct 1;98(7):1483-90.

11.

Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma.

Vrouenraets BC, Hart GA, Eggermont AM, Klaase JM, van Geel BN, Nieweg OE, Kroon BB.

J Am Coll Surg. 1999 May;188(5):522-30.

PMID:
10235581
12.

Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.

Lejeune FJ, Pujol N, Liénard D, Mosimann F, Raffoul W, Genton A, Guillou L, Landry M, Chassot PG, Chiolero R, Bischof-Delaloye A, Leyvraz S, Mirimanoff RO, Bejkos D, Leyvraz PF.

Eur J Surg Oncol. 2000 Nov;26(7):669-78.

PMID:
11078614
13.

TNF-based isolated limb perfusion in unresectable extremity desmoid tumours.

Grünhagen DJ, de Wilt JH, Verhoef C, van Geel AN, Eggermont AM.

Eur J Surg Oncol. 2005 Oct;31(8):912-6.

PMID:
16098709
14.

The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma.

Grunhagen DJ, de Wilt JH, Graveland WJ, van Geel AN, Eggermont AM.

Cancer. 2006 Jan 1;106(1):156-62.

15.

Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma.

Zogakis TG, Bartlett DL, Libutti SK, Liewehr DJ, Steinberg SM, Fraker DL, Alexander HR.

Ann Surg Oncol. 2001 Dec;8(10):771-8.

PMID:
11776490
16.

Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma.

Hayes AJ, Neuhaus SJ, Clark MA, Thomas JM.

Ann Surg Oncol. 2007 Jan;14(1):230-8.

PMID:
17066234
17.

One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases.

Grünhagen DJ, Brunstein F, Graveland WJ, van Geel AN, de Wilt JH, Eggermont AM.

Ann Surg. 2004 Dec;240(6):939-47; discussion 947-8.

18.

Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.

Kroon HM, Moncrieff M, Kam PC, Thompson JF.

Ann Surg Oncol. 2009 May;16(5):1184-92. doi: 10.1245/s10434-009-0323-x. Epub 2009 Feb 18.

PMID:
19224289
19.

Isolated limb perfusion with tumor necrosis factor and melphalan for nonresectable sSewart-Treves lymphangiosarcoma.

Lans TE, de Wilt JH, van Geel AN, Eggermont AM.

Ann Surg Oncol. 2002 Dec;9(10):1004-9.

PMID:
12464594
20.

TNF dose reduction in isolated limb perfusion.

Grünhagen DJ, de Wilt JH, van Geel AN, Graveland WJ, Verhoef C, Eggermont AM.

Eur J Surg Oncol. 2005 Nov;31(9):1011-9. Epub 2005 Aug 15.

PMID:
16099618

Supplemental Content

Support Center